Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841965 | 0.84 | MRGPRX4 (0.54) | HPGDUSP2MRGPRX4LMNAGAA | |
| SCHEMBL6321530 | 0.82 | MRGPRX4 (0.49) | HPGDUSP2MRGPRX4PDK1PDK2 | |
| SCHEMBL10751701 | 0.80 | LMNA (0.55) | HPGDUSP2MRGPRX4LMNAGAA | |
| SCHEMBL980656 | 0.78 | MEN1 (0.49) | HPGDLMNAALDH1A1POLBNPC1 | |
| SCHEMBL28463837 | 0.78 | MRGPRX4 (0.43) | HPGDUSP2MRGPRX4ALDH1A1POLB | |
| SCHEMBL31590796 | 0.77 | HPGD (0.68) | HPGDUSP2LMNAGAASMN1; SMN2 | |
| SCHEMBL9180503 | 0.77 | HPGD (0.68) | HPGDUSP2LMNAGAASMN1; SMN2 | |
| SCHEMBL19707579 | 0.77 | MRGPRX4 (0.58) | HPGDUSP2MRGPRX4LMNAGAA | |
| SCHEMBL4311940 | 0.76 | KDM4E (0.66) | HPGDUSP2PDK1PDK2PDK3 | |
| SCHEMBL29822237 | 0.76 | KDM4E (0.66) | HPGDUSP2PDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875626-B2 | 3,3,3-trifluoropropane-1-sulfonic acid 4-[1-(2-chlorophenyl)-3-methyl-4-oxo-5-piperidin-1-yl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine-2-yl]phenyl ester; treatment of obesity, psychiatric and neurological disorders | ASTRAZENECA AB (SE) | 2011-01-25 | — | — | US | disclosed |
| EP-1937679-B1 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20080312269-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080262026-A1 | Therapeutic Agents 684 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008119999-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008096151-A1 | PHARMACEUTICAL COMPOSITIONS OF CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| EP-1937679-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007039740-A2 | PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| US-7071207-B2 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | US | disclosed |
| EP-1432708-B1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORP (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| EP-1432708-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027114-A1 | PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO[3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262026-A1 | Therapeutic Agents 684 | GPR119, NLN, PYGB | HPGD 835/4885USP2 4406/4885MRGPRX4 997/4885 |
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | HPGD 565/4885USP2 4476/4885MRGPRX4 1456/4885 |
| US-20040224970-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity | GPR119, GIPR, PGC | HPGD 950/4885USP2 2402/4885MRGPRX4 600/4885 |
| US-20080312269-A1 | Therapeutic Agents | NLN, GRIN2C, GPR119 | HPGD 806/4885USP2 4378/4885MRGPRX4 1160/4885 |
| US-20060122215-A1 | Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity | GPR119, GIPR, PGC | HPGD 473/4885USP2 3022/4885MRGPRX4 1055/4885 |
| US-20080214611-A1 | Pharmaceutical Compositions - 659 | CNR1, CNR2, GPR18 | HPGD 1223/4885USP2 1680/4885MRGPRX4 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.